MediPharm Labs マネジメント

マネジメント基準チェック /34

MediPharm Labsの CEO はDavid Pidduckで、 Apr2022年に任命され、の在任期間は 2.58年です。の年間総報酬はCA$ 1.31Mで、 36%給与と64%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の4.08%を直接所有しており、その価値は€ 735.25K 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と5.4年です。

主要情報

David Pidduck

最高経営責任者

CA$1.3m

報酬総額

CEO給与比率	36.0%
CEO在任期間	2.6yrs
CEOの所有権	4.1%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

CEO報酬分析

MediPharm Labs の収益と比較して、David Pidduck の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-CA$12m
Jun 30 2024	n/a	n/a	-CA$13m
Mar 31 2024	n/a	n/a	-CA$14m
Dec 31 2023	CA$1m	CA$470k	-CA$13m
Sep 30 2023	n/a	n/a	-CA$16m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$26m
Dec 31 2022	CA$3m	CA$315k	-CA$30m

報酬と市場: Davidの総報酬 ($USD 930.25K ) は、 German市場 ($USD 476.59K ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Pidduck

2.6yrs

在職期間

CA$1,305,051

報酬

Mr. David A. Pidduck is Chief Executive Officer and Director at MediPharm Labs Corp. since April 20, 2022. Mr. Pidduck has been the Chief Executive Officer and President of Purdue Pharma Inc. since Septemb...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Keith Strachan	Co-Founder & President	5.8yrs	CA$819.48k	2.17% € 390.7k
Greg Hunter	Chief Financial Officer	3.8yrs	CA$957.75k	0.31% € 56.6k
Patrick McCutcheon	Founder	9.8yrs	CA$858.16k	データなし
Brett Moon	Vice President of Sales	4.5yrs	データなし	データなし
Kirk Binns	Executive Vice President of Global Accounts	5.8yrs	データなし	データなし

5.1yrs

平均在職期間

経験豊富な経営陣: MLZの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
David Pidduck	CEO & Director	2.6yrs	CA$1.31m	4.08% € 735.3k
Shelley Martin	Independent Director	4.4yrs	CA$64.49k	0.020% € 3.5k
Michael Bumby	Independent Director	1.6yrs	CA$34.45k	0.050% € 9.0k
Christopher Taves	Independent Chairman of the Board	4.3yrs	CA$87.14k	0.35% € 62.3k
Miriam McDonald	Member of the Science Advisory Board	5.6yrs	CA$32.40k	データなし
Leslie Brown	Member of the Science Advisory Board	5.6yrs	データなし	データなし
Matt Archibald	Member of the Science Advisory Board	5.6yrs	データなし	データなし
Markus Roggen	Member of the Science Advisory Board	5.6yrs	データなし	データなし
Arshad Hack	Member of the Science Advisory Board	5.6yrs	データなし	データなし
Jerry King	Member of the Science Advisory Board	5.6yrs	データなし	データなし
Carolina Landolt-Marticorena	Member of the Science Advisory Board	5.3yrs	データなし	データなし
Christopher Halyk	Independent Director	4.3yrs	CA$56.05k	0.043% € 7.7k

5.4yrs

平均在職期間

経験豊富なボード: MLZの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

MediPharm Labs マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

MediPharm Labs Corp. Announces Executive Changes

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

High number of new and inexperienced directors

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.013 loss in 3Q 2023)

MediPharm Labs Corp. to Report Q3, 2024 Results on Nov 14, 2024

MediPharm Labs Corp. Announces Executive Changes

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2023)

MediPharm Labs Corp. to Report Q2, 2024 Results on Aug 14, 2024

MediPharm Labs Corp., Annual General Meeting, Jun 26, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.01 loss in 1Q 2023)

MediPharm Labs Corp. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CA$0.04 loss per share (vs CA$0.11 loss in FY 2022)

MediPharm Labs Corp. to Report Q4, 2023 Results on Mar 27, 2024

Third quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 3Q 2022)

New minor risk - Profitability

Forecast to breakeven in 2024

MediPharm Labs Corp. to Report Q3, 2023 Results on Nov 14, 2023

Tilray Brands, Inc. (NasdaqGS:TLRY) acquired 1000652011 Ontario Inc. from MediPharm Labs Corp. (TSX:LABS) for CAD 8.5 million.

MediPharm Labs Corp. Settles an Outstanding Claim for $9,000,000 with HEXO Corp

MediPharm Labs Corp. Launches New GMP Products to the Australian Medical Cannabis Market

Medipharm Labs Corp. Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 2Q 2022)

MediPharm Labs Corp. to Report Q2, 2023 Results on Aug 14, 2023

MediPharm Labs Corp. Provides Update on US FDA Status

First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.03 loss in 1Q 2022)

MediPharm Labs Corp. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

MediPharm Labs Corp. (TSX:LABS) entered into a definitive arrangement agreement to acquire VIVO Cannabis Inc. (TSX:VIVO) from directors and officers of VIVO and others for CAD 11.1 million.

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.03 loss in 3Q 2021)

MediPharm Labs Corp. to Report Q3, 2022 Results on Nov 14, 2022

Onelife Botanicals Pty Ltd completed the acquisition of MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS).

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 2Q 2021)

MediPharm Labs Corp. to Report Q2, 2022 Results on Aug 15, 2022

Onelife Botanicals Pty Ltd entered into an agreement to acquire MediPharm Labs Australia Pty Ltd from MediPharm Labs Corp. (TSX:LABS) for AUD 6.9 million.

Dr. Paul Tam Resigns from the Board of Directors of MediPharm Labs Corp

First quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.07 loss in 1Q 2021)

MediPharm Labs Corp. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

MediPharm Labs Corp., Annual General Meeting, Jun 30, 2022

MediPharm Labs Corp. Announces Management Changes

Medipharm Labs Corp Launches CBG and Water-Soluble Products

Full year 2021 earnings released: CA$0.22 loss per share (vs CA$0.48 loss in FY 2020)

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

MediPharm Labs Corp. to Report Q4, 2021 Results on Mar 31, 2022

Medipharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

CEO of Asia Pacific & Director recently sold €60k worth of stock

MediPharm Labs Expands CBN Portfolio with Two New Products

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: CA$0.05 loss per share (vs CA$0.02 loss in 2Q 2020)

MediPharm Labs Corp. Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Founder & Chairman of the Board recently sold €329k worth of stock

Independent Director recently bought €206k worth of stock

MediPharm Labs Launches High-CBD Wellness Oils in Quebec

First quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.13 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.48 loss per share (vs CA$0.014 profit in FY 2019)

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Independent Director recently bought €132k worth of stock

Medipharm Labs Corp. Announces Plan to Launch New Over-The-Counter Products

MediPharm Labs Corp. has completed a Composite Units Offering in the amount of CAD 29 million.

Interim Chief Financial Officer has left the company

New 90-day high: €0.57

MediPharm Labs Corp. Appoints Greg Hunter as Chief Financial Officer, Effective February 8, 2021

MediPharm Labs Appoints Warren Everitt to Board of Directors

MediPharm Labs Corp. Enters a Supply Agreement with Nova Scotia Liquor Corporation

New 90-day low: €0.32

MediPharm Labs Corp. Announces Executive Changes

Revenue misses expectations

Third quarter 2020 earnings released: CA$0.11 loss per share

New 90-day low: €0.47

マネジメント基準チェック /34